Current location - Recipe Complete Network - Complete vegetarian recipes - How long can lung cancer live? How can lung cancer prolong life?
How long can lung cancer live? How can lung cancer prolong life?
People will encounter all kinds of things and get some diseases when they are alive. Some minor illnesses need not be too nervous, because they will not pose a threat to our life safety. But if it is cancer, we must actively treat it. At present, the highest incidence of cancer in China is lung cancer. So, how long can they live with lung cancer? How can lung cancer prolong life? Let's have a look.

1, lung cancer survival rate

Once diagnosed as "advanced lung cancer", many patients fall into infinite panic and feel that death is coming. According to statistics, in the treatment of lung cancer, only 15% of lung cancer patients can remove cancer cells by surgery, about 5% of lung cancer patients can not be operated because of the limitation of tumor growth site, and more than 70% of lung cancer patients can not be operated because their condition is not found in time. With stage ⅳ lung cancer as the representative, if not treated in time, the survival time is about 3-6 months.

In fact, how long patients with advanced lung cancer can live is not the same. Patients with advanced lung cancer can also prolong their survival as long as they are actively treated. Lung cancer is mainly divided into non-small cell lung cancer and small cell lung cancer. The probability of postoperative recurrence and metastasis of non-small cell lung cancer is also high. The 5-year postoperative survival rate of patients with non-small cell lung cancer was 44.5% in stage I, 36.65438 0% in stage II and less than 30% in a few stages IIIA. The earlier lung cancer is treated, the higher the survival rate of patients.

For patients with early small cell lung cancer, if surgical resection is combined with biotherapy and radiotherapy and chemotherapy in time, the three-year survival rate can reach 65%, the five-year survival rate can reach 50%, and there is no lymph node metastasis. However, if lung cancer has lymph node metastasis, the survival rate of patients will decrease by 15-30 percentage points.

Generally speaking, the survival time of patients with advanced lung cancer mainly depends on three factors, one is whether the treatment is timely, the other is the malignant degree of the tumor, and the third is whether the treatment is appropriate. We predict that in the near future, with the development of medical technology, the problem of lung cancer treatment will be completely overcome.

2. Symptoms of lung cancer

1. Hemoptysis: It is one of the most common symptoms in the early stage of lung cancer. Some scholars counted 3 12 cases, and found that 40.97% of them had this symptom for the first time, which manifested as sudden hemoptysis in middle-aged and elderly people, or blood in sputum, and some people had repeated pneumonia, vomiting blood and phlegm, and repeated attacks.

2. Clubbing finger: also known as drumming finger. It is characterized by hypertrophy of the first segment of fingers and toes, bending of the nail process, and often accompanied by pain. It has been reported abroad that 2 1% of lung cancer is accompanied by tussah fingers in the early stage, and most of the lung cancer disappears after surgery.

3. Arthritis: coexisting with tussah fingers, it can first appear when lung cancer lesions are small and difficult to be found, showing symptoms of wandering arthritis. Can appear elbow, knee, wrist, ankle, metacarpal joint burning pain, dyskinesia, elbow, kimono, fibula periosteum hyperplasia, known as rheumatoid arthritis-like arthritis. The pain can disappear after 24 hours of lung surgery.

4. Male and female breasts: one or both sides of male breasts are enlarged, such as women. A Pei and others in Japan investigated 267 cases of lung cancer, 7.5% of which were early male and female breasts, which were often ignored or even misdiagnosed as simple breast hyperplasia and removed.

5. Multiple systemic myositis: It is also one of the early symptoms of lung cancer. According to statistics, 85% of the typical symptoms of lung cancer appear in front of them, characterized by gradual general weakness and loss of appetite, and it is difficult to walk and get up in bed when the condition gets worse.

6. Other manifestations: hoarseness with asthma without obvious reasons; One side of the neck is obviously swollen; Small fissure in one eye, drooping eyelids, pupil contraction, etc. Sometimes it can happen when the pulmonary symptoms are not obvious.

3. Treatment of lung cancer

The number of death cases is 665438+ more than 1, which is the first cause of cancer death. When it comes to the treatment of lung cancer, people often think of traditional radiotherapy and chemotherapy first. However, radiotherapy and chemotherapy not only act on cancer cells, but also on normal cells, which inevitably brings great side effects and increases the pain of patients. "

Modern medical research has confirmed that the disorder of ErbB family, including EGFR and other three receptors, is closely related to the occurrence and deterioration of lung cancer. Targeted therapeutic drugs for EGFR and ErbB family receptors came into being. The first generation of targeted therapy drugs are tyrosine kinase inhibitors targeting EGFR receptors, but the binding with EGFR receptors is reversible, so drug-resistant mutations are prone to occur, leading to disease deterioration.

Afatinib, the second-generation targeted therapy drug, is the first ErbB family inhibitor in the world. Except EGFR, it can inhibit the whole ErbB receptor family, and this inhibition is irreversible. Therefore, compared with the first generation of targeted therapeutic drugs, afatinib can block the growth of cancer cells more comprehensively and permanently.

It needs to be clear that the first and second generation targeted drugs are used for the initial treatment of patients. At the same time, no matter from the clinical research results or clinical application, patients who use the second-generation TKI targeted drugs in the initial treatment benefit more and live longer. After the first or second generation TKI drug resistance, patients with T790M mutation should use the third generation drugs.